Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

Yet that was the dynamic with Neurocrine, with prognosticators at H.C. Wainwright, Guggenheim, and UBS (NYSE: UBS) all getting simultaneously less bullish on the company's future. Of the trio ...

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.7 billion market cap biopharmaceutical company, recently sold 700 shares of the company's common ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a ...

Furthermore, Neurocrine's lower-than-expected 2025 guidance for Ingrezza—a range of $2.5 billion to $2.6 billion—left investors puzzled and shares spiraling.

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $190.00. The company’s shares closed ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported Ingrezza Q4 about 1% below consensus estimates ...

In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Volatile trading persisted on the stock market last week as ...